{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040950","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.256567+00:00","generated_at":"2026-06-11T18:40:30.575566+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cullinan Oncology Q2 2023: Net loss $32.2M; cash $512.1M; pipeline advances with Phase 3 start","bullets":["Cash and investments $512.1M as of June 30, 2023; expected runway into 2026.","Net loss $32.2M in Q2 2023 vs $58.1M in Q1 2023; R&D expenses decreased due to one-time $25M upfront in Q1.","Phase 3 REZILIENT-3 study of zipalertinib in EGFR exon20 NSCLC first-line initiated in August 2023.","CLN-619 monotherapy expansion cohorts in endometrial and cervical cancers initiated; first patient dosed in Phase 1 CLN-978 for R/R B-NHL.","IND cleared for CLN-617; Phase 1 study expected to start in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040950","json":"https://secwatch.observer/filing/0000950170-23-040950.json","markdown":"https://secwatch.observer/filing/0000950170-23-040950.md","text":"https://secwatch.observer/filing/0000950170-23-040950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023040950/0000950170-23-040950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023040950/cgem-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:40:30.575566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"640b8aeababf57a1663d46591c8b0179ac21529a","claim":"Cullinan Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023040950/0000950170-23-040950-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}